168 related articles for article (PubMed ID: 37783879)
21. Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 MYC-amplified Medulloblastoma.
Coulter DW; Chhonker YS; Kumar D; Kesherwani V; Aldhafiri WN; McIntyre EM; Alexander G; Ray S; Joshi SS; Li R; Murry DJ; Chaturvedi NK
J Exp Clin Cancer Res; 2024 Jan; 43(1):18. PubMed ID: 38200580
[TBL] [Abstract][Full Text] [Related]
22. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
[TBL] [Abstract][Full Text] [Related]
23. c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients.
von Bueren AO; Oehler C; Shalaby T; von Hoff K; Pruschy M; Seifert B; Gerber NU; Warmuth-Metz M; Stearns D; Eberhart CG; Kortmann RD; Rutkowski S; Grotzer MA
BMC Cancer; 2011 Feb; 11():74. PubMed ID: 21324178
[TBL] [Abstract][Full Text] [Related]
24. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells.
von Bueren AO; Shalaby T; Rajtarova J; Stearns D; Eberhart CG; Helson L; Arcaro A; Grotzer MA
BMC Cancer; 2007 Jan; 7():19. PubMed ID: 17254356
[TBL] [Abstract][Full Text] [Related]
25. HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma.
da Cunha Jaeger M; Ghisleni EC; Cardoso PS; Siniglaglia M; Falcon T; Brunetto AT; Brunetto AL; de Farias CB; Taylor MD; Nör C; Ramaswamy V; Roesler R
J Mol Neurosci; 2020 Jun; 70(6):981-992. PubMed ID: 32056089
[TBL] [Abstract][Full Text] [Related]
26. Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine.
Moreira DC; Venkataraman S; Subramanian A; Desisto J; Balakrishnan I; Prince E; Pierce A; Griesinger A; Green A; Eberhardt CG; Foreman NK; Vibhakar R
J Neurooncol; 2020 May; 147(3):531-545. PubMed ID: 32180106
[TBL] [Abstract][Full Text] [Related]
27. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
[TBL] [Abstract][Full Text] [Related]
28. OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.
Xu Z; Murad N; Malawsky D; Tao R; Rivero-Hinojosa S; Holdhof D; Schüller U; Zhang P; Lazarski C; Rood BR; Packer R; Gershon T; Pei Y
Clin Cancer Res; 2022 Oct; 28(19):4278-4291. PubMed ID: 35736214
[TBL] [Abstract][Full Text] [Related]
29. A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
Wang D; Veo B; Pierce A; Fosmire S; Madhavan K; Balakrishnan I; Donson A; Alimova I; Sullivan KD; Joshi M; Erlander M; Ridinger M; Foreman NK; Venkataraman S; Vibhakar R
Neuro Oncol; 2022 Mar; 24(3):414-426. PubMed ID: 34477871
[TBL] [Abstract][Full Text] [Related]
30. Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
Han Y; Lindner S; Bei Y; Garcia HD; Timme N; Althoff K; Odersky A; Schramm A; Lissat A; Künkele A; Deubzer HE; Eggert A; Schulte JH; Henssen AG
Cancer Lett; 2019 Mar; 445():24-33. PubMed ID: 30611741
[TBL] [Abstract][Full Text] [Related]
31. Preferential sensitivity to HDAC inhibitors in tumors with CREBBP mutation.
Hellwig M; Merk DJ; Lutz B; Schüller U
Cancer Gene Ther; 2020 May; 27(5):294-300. PubMed ID: 31068675
[TBL] [Abstract][Full Text] [Related]
32. Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.
Cai B; Lyu H; Huang J; Wang S; Lee CK; Gao C; Liu B
Cancer Lett; 2013 Jul; 335(2):343-50. PubMed ID: 23459296
[TBL] [Abstract][Full Text] [Related]
33. ZEB1 is a Subgroup-Specific Marker of Prognosis and Potential Drug Target in Medulloblastoma.
Fratini L; Dalmolin MGS; Sinigaglia M; da Silveira Perla A; de Farias CB; Brunetto AL; Brunetto AT; da Cunha Jaeger M; Roesler R
Neuromolecular Med; 2023 Mar; 25(1):64-74. PubMed ID: 35716340
[TBL] [Abstract][Full Text] [Related]
34. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
36. BRCA2 deficiency increases sensitivity of medulloblastoma to Olaparib by inhibiting RAD51-mediated DNA damage repair system.
Yu J; Zhang C; Shi W; Rui H; Li H
Clin Transl Oncol; 2022 May; 24(5):919-926. PubMed ID: 35001340
[TBL] [Abstract][Full Text] [Related]
37. Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma.
Kumar V; Wang Q; Sethi B; Lin F; Kumar V; Coulter DW; Dong Y; Mahato RI
Biomaterials; 2021 Nov; 278():121138. PubMed ID: 34634662
[TBL] [Abstract][Full Text] [Related]
38. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
39. Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma.
Fiaschetti G; Castelletti D; Zoller S; Schramm A; Schroeder C; Nagaishi M; Stearns D; Mittelbronn M; Eggert A; Westermann F; Ohgaki H; Shalaby T; Pruschy M; Arcaro A; Grotzer MA
Oncogene; 2011 Jun; 30(25):2823-35. PubMed ID: 21317922
[TBL] [Abstract][Full Text] [Related]
40. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
